Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin(TM) is Safe and Well-Tolerated in HCV Patients

Peregrine Pharmaceuticals to Present at Roth Capital Partners 18th Annual OC Conference

Peregrine Announces Completion of Planned Patient Enrollment and Dosing in Initial Tarvacin(TM) Anti-Viral Hepatitis C Phase 1 Trial

Peregrine Pharmaceuticals to Present at 2006 BIO CEO Conference

Peregrine Announces Acceleration of Its Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program

Peregrine Pharmaceuticals Announces Second Defense Department Grant for Preclinical Tarvacin Prostate Cancer Studies

Newly Published Data Shows Potential of Peregrine's Tarvacin(TM) to Treat Primary and Metastatic Pancreatic Cancer

Peregrine Pharmaceuticals Reports Fiscal Year 2006 Second Quarter Results

Peregrine's Subsidiary Begins First Commercial Stage Drug Manufacturing Project

Peregrine Pharmaceuticals to Host Second Quarter FY2006 Conference Call